Floatz logo

mk-3475

Lymphoma, T-Cell, Peripheral

Fox Chase Cancer Centermonoclonal_antibodyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

136 Active assets in the Lymphoma, T-Cell, Peripheral cohort.

Asset / SponsorPhaseRating
Inno-206
BeBetter Med Inc
Phase 4BBB
PREDNISONE TABLETS
Tarapeutics Science Inc.
Phase 4BBB
Pralatrexate
Peking University People's Hospital
Phase 4BBB
(+)-VINCRISTINE
BeBetter Med Inc
Phase 4BBB
Cyclophosphamide
Tarapeutics Science Inc.
Phase 4BBB

View all 50 →

Same molecule, other indications

mk-3475 is also rated in:

melanomaDormant
B
Indicative ·
61 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
60 / 100
View asset →
MSI Positive Non-Colorectal CancersDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →